Genaera Corporation

Genaera Corporation researches and develops drugs to address obesity, type 2 diabetes, and respiratory diseases. The company's leading clinical candidate drug, Trodusquemine, is a small molecule in Phase I trials for the treatment of obesity and type 2 diabetes. Its product portfolio also includes Anti-Interleukin-9, a product in Phase II clinical trials for asthma treatment, and LOCILEX cream, a topical antibiotic cream currently in Phase III clinical trials for the treatment of diabetic foot ulcer infections. The company has signed a collaborative agreement with MedImmune aimed at developing and commercializing therapies related to its Anti-Interleukin-9 program for asthma treatment.